In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Theriva Biologics (TOVX – Research Report), with a price target of $4.00. The company’s shares opened today at $0.66.
McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Lineage Therap, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of -28.4% and a 20.49% success rate on recommended stocks.
Theriva Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.50 and a one-year low of $0.39. Currently, Theriva Biologics has an average volume of 37.95K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Read More on TOVX:
- Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
- Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results
- Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
- Theriva Biologics reports FY22 EPS ($1.31) vs ($1.90) last year
- Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
